RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Xynomic Pharma, a China-US oncology pharma, will start a Phase I/II trial of its lead candidate, the novel HDAC inhibitor Abexinostat, in combination with Janssen Pharma’s Imbruvica® (ibrutinib). Imbruvica is a first-in-class BTK inhibitor that quickly acquired blockbuster sales in several hard-to-treat cancer types. The trial will be conducted at New York City’s Memorial Sloan Kettering Cancer Center in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
Source: China Biotoday
